GRI Bio Inc GRI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GRI is a good fit for your portfolio.
News
-
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
-
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
-
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
-
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
-
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
-
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
-
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
-
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
Trading Information
- Previous Close Price
- $0.41
- Day Range
- $0.39–0.42
- 52-Week Range
- $0.38–49.28
- Bid/Ask
- $0.39 / $0.41
- Market Cap
- $1.31 Mil
- Volume/Avg
- 43,425 / 301,629
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio’s program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 4
- Website
- https://www.gribio.com
Valuation
|
Metric
|
GRI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.02 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GRI
|
|---|---|
Quick Ratio | 0.67 |
Current Ratio | 1.09 |
Interest Coverage | −5.26 |
Quick Ratio
GRI
Profitability
|
Metric
|
GRI
|
|---|---|
Return on Assets (Normalized) | −412.67% |
Return on Equity (Normalized) | −1,295.94% |
Return on Invested Capital (Normalized) | −940.56% |
Return on Assets
GRI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Czmcftyyy | Ngl | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nrtfcqrf | Ppcyy | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tnjbqrkt | Mwckxm | $105.3 Bil | |
MRNA
| Moderna Inc | Khhmtxjl | Hgc | $47.0 Bil | |
ARGX
| argenx SE ADR | Bxwvzjgx | Qmhk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gnzywdhsw | Ttdv | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dgvymxd | Rjjqgm | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zzrkkbcyd | Cvvqdw | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Smlxxvnmz | Khqnfb | $12.7 Bil | |
INCY
| Incyte Corp | Vrrlfkzc | Dmckgt | $12.0 Bil |